Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective (Q36608336)

15 August 2017

1 reference

title

Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective (English)

1 reference

15 August 2017

Graham Jackson

1

1 reference

15 August 2017

Piero Montorsi

series ordinal

2

1 reference

15 August 2017

Melvin D Cheitlin

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

68

1 reference

15 August 2017

issue

3 Suppl

1 reference

15 August 2017

page(s)

47-60

1 reference

A 4-year update on the safety of sildenafil citrate (Viagra).

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Structure and function of cGMP-dependent protein kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Store-operated calcium entry in vascular endothelial cells is inhibited by cGMP via a protein kinase G-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Fundamentals of endothelial function for the clinical cardiologist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Effects of sildenafil citrate on human hemodynamics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Overall cardiovascular profile of sildenafil citrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Hemodynamic effects of sildenafil in patients with stable ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Hemodynamic effects of sildenafil in men with severe coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Effects of Sildenafil Citrate (Viagra®) on Hemodynamic Parameters during Exercise Testing and Occurrence of Ventricular Arrhythmias in Patients with Erectile Dysfunction and Cardiovascular Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Sildenafil citrate does not affect cardiac contractility in human or dog heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Hemodynamic effects of sildenafil citrate and isosorbide mononitrate in men with coronary artery disease and erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Sildenafil citrate does not affect QT intervals and QT dispersion: an important observation for drug safety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Evaluation of vardenafil and sildenafil on cardiac repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Treatment program for erectile dysfunction in patients with cardiovascular diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Sexual activity as a trigger for cardiovascular events: what is the risk?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.05.047

10.1016/J.UROLOGY.2006.05.047

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference